GSK Expected To Reveal China Sales Decline Half That Of Third Quarter
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline, whose problems triggered a drug-industry compliance scandal in China, is expected to report that its sales losses there decreased during the latest reporting quarter.